PMID- 34964747
OWN - NLM
STAT- MEDLINE
DCOM- 20220201
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 47
DP  - 2021 Nov 24
TI  - Follow-up care over 12 months of patients with prostate cancer in Spain: A 
      multicenter prospective cohort study.
PG  - e27801
LID - 10.1097/MD.0000000000027801 [doi]
LID - e27801
AB  - The therapeutic approach is crucial to prostate cancer prognosis. We describe 
      treatments and outcomes for a Spanish cohort of patients with prostate cancer 
      during the first 12 months after diagnosis and identify the factors that 
      influenced the treatment they received.This multicenter prospective cohort study 
      included patients with prostate cancer followed up for 12 months after diagnosis. 
      Treatment was stratified by factors such as hospital, age group (<70 and 
      >/=70 years), and D'Amico cancer risk classification. The outcomes were Eastern 
      Cooperative Oncology Group (ECOG) performance status, adverse events (AEs), and 
      mortality. The patient characteristics associated with the different treatment 
      modalities were analyzed using multivariate logistic regression.We included 470 
      men from 7 Spanish tertiary hospitals (mean (standard deviation) age 67.8 (7.6) 
      years), 373 (79.4%) of which received treatment (alone or in combination) as 
      follows: surgery (n = 163; 34.7%); radiotherapy (RT) (n = 149; 31.7%); and 
      hormone therapy (HT) (n = 142; 30.2%). The remaining patients (n = 97) were 
      allocated to no treatment, that is, watchful waiting (14.0%) or active 
      surveillance (5.7%). HT was the most frequently administered treatment during 
      follow-up and RT plus HT was the most common therapeutic combination. Surgery was 
      more frequent in patients aged <70, with lower histologic tumor grades, Gleason 
      scores <7, and lower prostate-specific antigen levels; while RT was more frequent 
      in patients aged >/=70 with histologic tumor grade 4, and higher ECOG scores. HT 
      was more frequent in patients aged >/=70, with histologic tumor grades 3 to 4, 
      Gleason score >/=8, ECOG >/=1, and higher prostate-specific antigen levels. The 
      number of fully active patients (ECOG score 0) decreased significantly during 
      follow-up, from 75.3% at diagnosis to 65.1% at 12 months (P < .001); 230 (48.9%) 
      patients had at least 1 AE, and 12 (2.6%) patients died.Surgery or RT were the 
      main curative options. A fifth of the patients received no treatment. Palliative 
      HT was more frequently administered to older patients with higher tumor grades 
      and higher Gleason scores. Close to half of the patients experienced an AE 
      related to their treatment.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Bonfill, Xavier
AU  - Bonfill X
AD  - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.
AD  - Iberoamerican Cochrane Centre, Institute of Biomedical Research Sant Pau (IIB 
      Sant Pau), Barcelona, Spain.
AD  - Public Health and Clinical Epidemiology Service, Hospital de la Santa Creu i Sant 
      Pau, Spain.
AD  - Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Martinez-Zapata, Maria Jose
AU  - Martinez-Zapata MJ
AUID- ORCID: 0000-0002-5836-1138
AD  - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.
AD  - Iberoamerican Cochrane Centre, Institute of Biomedical Research Sant Pau (IIB 
      Sant Pau), Barcelona, Spain.
AD  - Cochrane Ecuador, Centro de Investigacion en Salud Publica y Epidemiologia 
      Clinica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo, Universidad 
      Tecnologica Equinoccial, Quito, Ecuador.
FAU - Vernooij, Robin Wm
AU  - Vernooij RW
AD  - Iberoamerican Cochrane Centre, Institute of Biomedical Research Sant Pau (IIB 
      Sant Pau), Barcelona, Spain.
FAU - Sanchez, Maria Jose
AU  - Sanchez MJ
AD  - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.
AD  - Escuela Andaluza de Salud Publica, Instituto de Investigacion Biosanitaria de 
      Granada, Barcelona, Spain.
FAU - Morales-Suarez-Varela, Maria
AU  - Morales-Suarez-Varela M
AD  - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.
AD  - Unit of Public Health and Environmental Care, Department of Preventive Medicine, 
      University of Valencia, Valencia, Spain.
FAU - Emparanza, Jose Ignacio
AU  - Emparanza JI
AD  - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.
AD  - Clinical Epidemiology Unit, Hospital Universitario Donostia, BioDonostia, San 
      Sebastian, Spain.
FAU - Ferrer, Montse
AU  - Ferrer M
AD  - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.
AD  - Health Services Research Group, IMIM (Hospital del Mar Medical Research 
      Institute), Barcelona, Spain.
FAU - Pijoan, Jose Ignacio
AU  - Pijoan JI
AD  - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.
AD  - Clinical Epidemiology Unit, Hospital, Universitario Cruces, Biocruces, Barakaldo, 
      Spain.
FAU - Palou, Joan
AU  - Palou J
AD  - Fundacio Puigvert, Barcelona, Spain.
FAU - Madrid, Eva
AU  - Madrid E
AD  - Cochrane Centre Universidad de Valparaiso, Chile, Interdisciplinary Centre for 
      Health Studies CIESAL, Department of Public Health - School of Medicine - 
      Universidad de Valparaiso, Chile.
FAU - Abraira, Victor
AU  - Abraira V
AD  - Unidad de Bioestadistica Clinica, Hospital Universitario Ramon y Cajal, IRYCIS, 
      Madrid, Spain.
FAU - Zamora, Javier
AU  - Zamora J
AD  - CIBER de Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.
AD  - Unidad de Bioestadistica Clinica, Hospital Universitario Ramon y Cajal, IRYCIS, 
      Madrid, Spain.
AD  - Barts and the London School of Medicine and Dentistry, Queen Mary University 
      London, London, UK.
CN  - EMPARO-CU study group
LA  - eng
GR  - PS09/01204/Instituto de Salud Carlos III/
GR  - PS09/01619/Instituto de Salud Carlos III/
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - *Aftercare
MH  - Aged
MH  - Antineoplastic Agents, Hormonal/*therapeutic use
MH  - Brachytherapy/*adverse effects
MH  - *Chemotherapy, Adjuvant
MH  - Cohort Studies
MH  - Humans
MH  - Male
MH  - Neoplasm Grading
MH  - Prospective Studies
MH  - Prostate-Specific Antigen
MH  - Prostatectomy/*adverse effects
MH  - Prostatic Neoplasms/pathology/*therapy
MH  - Spain/epidemiology
MH  - Treatment Outcome
PMC - PMC8615301
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2021/12/30 06:00
MHDA- 2022/02/02 06:00
PMCR- 2021/11/24
CRDT- 2021/12/29 12:22
PHST- 2020/04/24 00:00 [received]
PHST- 2021/10/28 00:00 [accepted]
PHST- 2021/12/29 12:22 [entrez]
PHST- 2021/12/30 06:00 [pubmed]
PHST- 2022/02/02 06:00 [medline]
PHST- 2021/11/24 00:00 [pmc-release]
AID - 00005792-202111240-00022 [pii]
AID - MD-D-20-03742 [pii]
AID - 10.1097/MD.0000000000027801 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Nov 24;100(47):e27801. doi: 
      10.1097/MD.0000000000027801.